GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Cash Receipts from Fees and Commissions

Aurinia Pharmaceuticals (FRA:IKAP) Cash Receipts from Fees and Commissions


View and export this data going back to 2000. Start your Free Trial

What is Aurinia Pharmaceuticals Cash Receipts from Fees and Commissions?

Cash Receipts from Fees and Commissions only applicable to companies reporting Cash Flow from Operations in direct method.


Aurinia Pharmaceuticals (FRA:IKAP) Business Description

Industry
Traded in Other Exchanges
Address
4464 Markham Street, Suite 1203, Victoria, BC, CAN, V8Z 7X8
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.